July 2 (Reuters) - Cartesian Therapeutics (RNAC.O), opens new tab said on Tuesday that its experimental therapy helped reduce symptoms of a rare, immune-related disorder, meeting the main goal in a ...
Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases, eliminating the need for preconditioning chemotherapy. Lead candidate Descartes-08 showed promising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results